The group's principal activity is to develop and market a proprietary drug delivery system. This system is capable of introducing and removing high dose chemotherapy agents to a diseased organ system while greatly inhibiting their entry into the general circulation system. The group has developed a system, the delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. The group is in the development stage and conducts clinical trials designed to secure marketing approval for the system in the United States. The delcath system kit includes the following disposable components: infusion catheter, double balloon catheter, extracorporeal filtration circuit, filters and return catheter.
